Second-line treatment of non-small cell lung cancer: Big targets, small progress; small targets, big progress?

Journal of Thoracic Oncology

Volumn 1, Issue 9, 2006, Pages 927-928

  Hanna, Nasser ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; GEFITINIB; PEMETREXED; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TAXOID; UNCLASSIFIED DRUG;

CANCER THERAPY; CLINICAL TRIAL; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; CONTROLLED CLINICAL TRIAL; FEMALE; LUNG TUMOR; MALE; MORTALITY; NOTE; PHASE 2 CLINICAL TRIAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; PIPERIDINES; PROBABILITY; PROGNOSIS; PYRIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 34247897225     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200611000-00001     Document Type: Editorial

References (6)

1. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma (Abstract). Proc Am Soc Clin Oncol 2006;24:364s.
2. Socinski M, N'ovello S, Sanchez J, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial (Abstract). Proc Am Soc Clin Oncol 2006;24:364s.
3. Natale R, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, doubleblind, randomized phase II trial (Abstract). Proc Am Soc Clin Oncol 2006;24:364s.
4. Heymach J, Johnson B, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results (Abstract). Proc Am Soc Clin Oncol 2006;24:368s.
5. Fehrenbacher L, ONeill V, Belani P, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 2006;24:379s.
6. Lynch T, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.